ABBV · News · 20260908N

Cash Flow and Capital Allocation

AbbVie Inc. · 2026-09-08 · Importance 38 · Surprise 24

A third-party report stated that AbbVie returned approximately $62 billion to shareholders through dividends and buybacks over the five years ended September 2026. The reported capital returns were supported by free cash flow generated by the immunology portfolio, particularly SKYRIZI and RINVOQ. The report said AbbVie continues to grow its dividend despite declining HUMIRA sales. It also stated that management aims to reduce net leverage within three years following the Apogee acquisition.

Key facts